Diabetes and heart failure frequently coexist, creating a complex clinical challenge that demands integrated treatment strategies. The excess risk of heart failure in patients with type 2 diabetes is well established, with diabetes conferring a two- to fourfold increase in heart failure incidence. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative class of medications that not only improve glycemic control but also independently reduce the risk of heart failure hospitalization and cardiovascular death. Understanding the mechanisms and evidence behind these benefits is essential for clinicians managing diabetic patients at elevated cardiovascular risk.

What Are SGLT2 Inhibitors?

SGLT2 inhibitors, also known as gliflozins, are a class of oral hypoglycemic agents that selectively block the sodium-glucose cotransporter-2 protein located in the proximal tubule of the kidney. Under normal physiology, the kidney reabsorbs approximately 90% of filtered glucose via SGLT2, with the remaining 10% reabsorbed by SGLT1 in the distal tubule. By inhibiting SGLT2, these drugs reduce glucose reabsorption, leading to significant glycosuria and a corresponding reduction in plasma glucose levels. This insulin-independent mechanism makes SGLT2 inhibitors effective across a wide range of disease stages and reduces the risk of hypoglycemia when used as monotherapy.

The major drugs in this class include empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin. Each has been studied in large cardiovascular outcomes trials, and their benefits extend beyond glycemic control to include weight loss, blood pressure reduction, and direct cardiorenal protection. The unique pharmacodynamic profile of SGLT2 inhibitors has positioned them as cornerstone therapy in the management of type 2 diabetes, particularly in patients with established cardiovascular disease or chronic kidney disease.

How Do SGLT2 Inhibitors Reduce Heart Failure Risk?

The reduction in heart failure risk observed with SGLT2 inhibitors is not solely attributable to improvements in glycemic control. Instead, it results from a combination of hemodynamic, metabolic, and cellular mechanisms that collectively unload the heart and improve its efficiency. Clinical trials consistently demonstrate a 30% to 40% relative risk reduction in heart failure hospitalization with SGLT2 inhibitor therapy, an effect that emerges early after treatment initiation and is independent of baseline glycemic status or kidney function.

Hemodynamic Effects

SGLT2 inhibitors induce a modest osmotic diuresis and natriuresis by excreting glucose and sodium in the urine. This reduces plasma volume, decreases preload, and lowers left ventricular filling pressures. The reduction in blood volume also contributes to a decrease in arterial blood pressure, typically in the range of 3 to 5 mm Hg systolic, which reduces afterload. Lower preload and afterload together decrease myocardial wall stress, reduce oxygen demand, and improve overall cardiac efficiency. The diuretic effect is distinct from that of loop diuretics because SGLT2 inhibitors act early in the nephron and do not activate the renin-angiotensin-aldosterone system to the same degree. This hemodynamic profile is particularly beneficial in patients with heart failure with preserved ejection fraction, where volume overload and hypertension are central pathophysiologic drivers.

Metabolic Effects

Beyond hemodynamics, SGLT2 inhibitors produce favorable metabolic changes that support cardiac health. The urinary loss of glucose creates a net calorie deficit of approximately 200 to 300 kcal per day, leading to gradual weight loss and improvement in insulin sensitivity. Reduced adiposity, especially visceral fat, decreases systemic inflammation and lowers the production of pro-inflammatory cytokines that contribute to myocardial dysfunction.

A more direct cardiac metabolic benefit arises from the shift in myocardial substrate utilization. SGLT2 inhibition increases circulating ketone bodies (beta-hydroxybutyrate and acetoacetate) by promoting lipolysis and hepatic ketogenesis. The failing heart has reduced efficiency in using fatty acids and glucose as fuel; ketones serve as a superfuel that can be oxidized more efficiently than either fatty acids or glucose in the stressed myocardium. This metabolic shift improves cardiac energetics, increases ATP production per unit of oxygen consumed, and mitigates mitochondrial dysfunction. Ketones also inhibit the NLRP3 inflammasome and reduce oxidative stress, providing anti-inflammatory and anti-oxidant effects that protect cardiac myocytes.

Cellular and Molecular Effects

At the cellular level, SGLT2 inhibitors reduce intracellular sodium and calcium concentrations in cardiomyocytes, which improves mitochondrial calcium handling and reduces reactive oxygen species generation. They also suppress the activity of the Na+/H+ exchanger (NHE1) in the heart, which reduces sodium influx and indirectly lowers cytosolic calcium. This reduces diastolic calcium overload, improves relaxation, and decreases the propensity for arrhythmias.

SGLT2 inhibitors have been shown to attenuate cardiac fibrosis and remodeling in experimental models. They reduce the expression of transforming growth factor-beta, collagen deposition, and fibroblast activation. This antifibrotic effect preserves myocardial compliance and limits the progression from hypertrophy to heart failure. Additionally, these drugs improve endothelial function by increasing nitric oxide bioavailability and reducing vascular stiffness, which supports coronary perfusion and systemic vascular health.

Impact on Cardiac Function

Echocardiographic and cardiac magnetic resonance imaging studies in human subjects have confirmed that SGLT2 inhibitor therapy is associated with improvements in left ventricular filling pressures, ejection fraction, and global longitudinal strain. These changes are consistent with reduced congestion and improved myocardial contractility. In patients with heart failure with reduced ejection fraction, SGLT2 inhibitors increase left ventricular ejection fraction by 2 to 5 percentage points over 6 to 12 months, a magnitude of improvement comparable to that seen with established neurohormonal antagonists. Importantly, these benefits occur regardless of whether the patient has diabetes, indicating that the cardioprotective mechanisms are independent of glycemic effects.

Clinical Evidence Supporting Their Use

The evidence base for SGLT2 inhibitors in heart failure prevention and treatment is among the strongest in cardiovascular medicine. Landmark randomized controlled trials have provided high-certainty evidence that these drugs reduce heart failure events across a broad spectrum of patients, from primary prevention in type 2 diabetes to established heart failure with and without diabetes.

EMPA-REG OUTCOME Trial

The EMPA-REG OUTCOME trial, published in 2015, was the first cardiovascular outcomes study to demonstrate a mortality benefit with an SGLT2 inhibitor. In 7020 patients with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14%. The most striking finding was a 38% relative risk reduction in death from cardiovascular causes and a 35% reduction in hospitalization for heart failure. The heart failure benefit emerged within weeks of randomization and persisted throughout the trial, strongly supporting a direct hemodynamic effect rather than a delayed atherosclerotic benefit. The findings of EMPA-REG OUTCOME reshaped diabetes treatment guidelines and elevated empagliflozin to a first-line therapy for patients with type 2 diabetes and cardiovascular disease. View the EMPA-REG OUTCOME trial.

CANVAS and CANVAS-R

The CANVAS Program integrated data from two trials involving 10,142 participants with type 2 diabetes and either a history of cardiovascular disease or multiple risk factors. Canagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14%, with a 33% reduction in hospitalization for heart failure. These results were consistent across patient subgroups and confirmed the class effect for heart failure risk reduction.

DAPA-HF Trial

The DAPA-HF trial marked a paradigm shift by demonstrating the efficacy of dapagliflozin in patients with heart failure with reduced ejection fraction, irrespective of diabetes status. Among 4744 patients with New York Heart Association class II-IV symptoms and a left ventricular ejection fraction of 40% or less, dapagliflozin reduced the primary composite outcome of worsening heart failure or cardiovascular death by 26%. The benefit was consistent in patients with and without type 2 diabetes, indicating that the heart failure protection is independent of glycemic effects. Hospitalization for heart failure was reduced by 30%, and cardiovascular death was reduced by 18% over a median follow-up of 18 months. Review the DAPA-HF trial results.

DAPA-CKD and EMPEROR-Reduced Trials

The DAPA-CKD trial extended the evidence to patients with chronic kidney disease, with or without diabetes. Dapagliflozin reduced the composite of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, or death from renal or cardiovascular causes by 39%. Heart failure hospitalization was reduced by 29% in this population. The EMPEROR-Reduced trial evaluated empagliflozin in 3730 patients with heart failure with reduced ejection fraction, including those with and without diabetes. Empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25%, with a 31% reduction in heart failure hospitalizations. The benefit was consistent across ejection fraction categories, age, sex, and background therapy, reinforcing the role of SGLT2 inhibitors as foundational therapy in heart failure management.

Meta-Analyses and Real-World Evidence

Multiple meta-analyses aggregating data from the cardiovascular outcomes trials have confirmed that SGLT2 inhibitors reduce the risk of hospitalization for heart failure by approximately 30% to 35% in patients with type 2 diabetes. The benefit appears early, is consistent across patient subgroups, and is independent of background glucose-lowering therapy. Real-world observational studies have replicated these findings, showing reductions in heart failure hospitalization and all-cause mortality in clinical practice settings. The consistency between trial data and real-world evidence strengthens confidence in the class effect. Read the AHA scientific statement on SGLT2 inhibitors.

Implications for Treatment

The compelling evidence for heart failure risk reduction with SGLT2 inhibitors has led to major changes in clinical practice guidelines. The American Diabetes Association, the European Society of Cardiology, the American College of Cardiology, and the American Heart Association now recommend SGLT2 inhibitors as first-line therapy for patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease. For patients with type 2 diabetes and multiple cardiovascular risk factors, SGLT2 inhibitors are recommended as part of a comprehensive approach to cardiorenal prevention.

Patient Selection

SGLT2 inhibitors are indicated for diabetic patients with established cardiovascular disease, heart failure with reduced ejection fraction, or chronic kidney disease with albuminuria. In patients with type 2 diabetes who have not yet developed heart failure, SGLT2 inhibitor therapy should be considered when there is a high risk of progression, such as in those with concomitant hypertension, left ventricular hypertrophy, or prior myocardial infarction. The benefit appears to be greatest in patients with higher baseline risk, but even those at moderate risk derive meaningful reductions in heart failure events.

For patients with established heart failure, SGLT2 inhibitors are now considered a pillar of guideline-directed medical therapy, alongside angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. The DAPA-HF and EMPEROR-Reduced trials included patients already receiving optimal background therapy, demonstrating additive benefit. The use of SGLT2 inhibitors should therefore be considered in all patients with heart failure with reduced ejection fraction, regardless of diabetes status, unless contraindicated.

Safety Considerations

SGLT2 inhibitors are generally well tolerated, but clinicians must be aware of potential adverse effects to ensure safe use. The most common side effects include genital mycotic infections in both men and women, attributed to the glucose-rich urine that promotes fungal overgrowth. These infections are typically mild and respond to standard antifungal therapy, but patient education on hygiene is important. Urinary tract infections occur at a slightly increased frequency, though the absolute risk is low.

A rare but serious adverse event associated with SGLT2 inhibitor use is euglycemic diabetic ketoacidosis, defined as ketoacidosis with blood glucose levels below 250 mg/dL. This condition is more common in patients with type 1 diabetes but can occur in type 2 diabetes under conditions of stress, illness, reduced caloric intake, or insulin dose reduction. Patients should be counseled to temporarily discontinue the medication during prolonged fasting, acute illness, or before elective surgery. Volume depletion and hypotension can occur, particularly in elderly patients or those receiving loop diuretics. Dose adjustment for renal function is required for some agents, although the heart failure benefit has been demonstrated across a wide range of kidney function. See the FDA safety information for SGLT2 inhibitors.

Integration With Other Therapies

SGLT2 inhibitors can be combined with other glucose-lowering agents, including metformin, glucagon-like peptide-1 receptor agonists, and insulin. The combination of an SGLT2 inhibitor with a GLP-1 receptor agonist provides additive benefits for glycemic control, weight reduction, and cardiovascular protection, and is recommended for patients with type 2 diabetes and established atherosclerotic cardiovascular disease. In patients with heart failure, SGLT2 inhibitors are used alongside standard heart failure therapies, and data from the EMPEROR-Reduced trial suggest that the benefit is preserved in patients taking sacubitril/valsartan.

Monitoring and Follow-Up

Patients initiating SGLT2 inhibitor therapy should have baseline assessment of kidney function, volume status, and blood pressure. After starting treatment, monitoring of renal function within the first 2 to 4 weeks is prudent, especially in patients with chronic kidney disease. Long-term monitoring should include periodic assessment of hemoglobin A1c, weight, blood pressure, and heart failure symptoms. Patients should be educated about the signs of dehydration, ketoacidosis, and genital infections. The early and sustained reduction in heart failure risk means that clinicians should not delay initiation of SGLT2 inhibitor therapy in appropriate patients while awaiting optimization of other risk factors.

Conclusion

SGLT2 inhibitors represent a significant advancement in the management of type 2 diabetes and the prevention of heart failure. Through hemodynamic unloading, metabolic optimization, anti-fibrotic effects, and improved cardiac energetics, these drugs address core pathophysiologic mechanisms that drive heart failure progression. The clinical trial evidence is robust and consistent, showing a 30% to 40% reduction in heart failure hospitalization across diverse patient populations. Guidelines have rapidly evolved to position SGLT2 inhibitors as first-line therapy for diabetic patients with cardiovascular risk, heart failure, or chronic kidney disease. Clinicians should incorporate these agents into routine practice with appropriate patient selection and monitoring. The shift from a glucose-centric approach to a cardiorenal protective strategy marks a new era in diabetes care, one that prioritizes outcomes that matter most to patients: living longer, staying out of the hospital, and maintaining quality of life. Access the ADA Standards of Care for SGLT2 inhibitor recommendations.